Ergomed has announced positive top line data from its Phase II trial of PeproStat™. The liquid haemostat met the primary efficacy endpoint of superiority over standard of care in time to haemostatis across all surgery types tested. PeproStat™ offers a differentiated approach to current products in the haemostat market in that it is manufactured from blood-free components and formulated in a ready-to-use solution. Ergomed now intends to undertake a Phase III trial evaluating PeproStat™ in an enla ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Ergomed - Positive top line PeproStat™ Phase II data
- Published:
23 Oct 2017 -
Author:
Sheena Berry -
Pages:
7
Ergomed has announced positive top line data from its Phase II trial of PeproStat™. The liquid haemostat met the primary efficacy endpoint of superiority over standard of care in time to haemostatis across all surgery types tested. PeproStat™ offers a differentiated approach to current products in the haemostat market in that it is manufactured from blood-free components and formulated in a ready-to-use solution. Ergomed now intends to undertake a Phase III trial evaluating PeproStat™ in an enla ....